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ABSTRACT Based on the structure of FKBP12 complexed with FK506 or rapamycin, with computer-aided design, two
neurotrophic ligands, (3R)-4-(p-Toluenesulfonyl)-1,4-thiazane-3-carboxylic acid-L-Leucine ethyl ester and (3R)-4-(p-Toluene-
sulfonyl)-1,4-thiazane-3-carboxylic acid-L-phenylalanine benzyl ester, were designed and synthesized. Fluorescence experi-
ments were used to detect the binding afﬁnity between FKBP12 and these two ligands. Complex structures of FKBP12 with
these two ligands were obtained by x-ray crystallography. In comparing FKBP12-rapamycin complex and FKBP12-FK506
complex as well as FKBP12-GPI-1046 solution structure with these new complexes, signiﬁcant volume and surface area effects
and obvious contact changes were detected which are expected to cause their different binding energies—showing these two
novel ligands will become more effective neuron regeneration drugs than GPI-1046, which is currently undergoing phase II
clinical trail as a neurotrophic drug. Analysis of volume and surface area effects also gives a new clue for structure-based drug
design.
INTRODUCTION
The immunophilins are a family of phylogenically conserved
binding proteins possessing peptidal prolyl isomerase (PPI)
activity (rotamase), including cyclophilin and FK506 binding
protein (FKBPs) (Hauske et al., 1992). Immunosuppressant
drugs such as cyclosporin A, FK506, and rapamycin can in-
hibit their PPI activity. Furthermore, associatedwith immuno-
suppressant binding, they can interact with calcineurin to
block calcineurin-mediated T-cell activation, resulting in the
immunosuppressant effects (Clipstone and Crabtree 1992;
Grifﬁth et al., 1995; Liu et al., 1991). FKBPs play multiple
roles in cell physiology. Especially, besides the PPIase
activity and immunosuppressant function, FKBP12 takes the
control of signaling modulation via the membrane-bound
EGF/TGF-b receptor and also controls intracellular calcium
ion ﬂow by binding inositol(1,4,5) trisphosphate(IP3)/
ryanodine receptor (Herdegan et al., 2000). Several FKBP12
complex structures have been determined, such as FKBP12-
FK506-calcineurin (Grifﬁth et al., 1995; Kissinger et al.,
1995), FKBP12-rapamycin-FRAP-binding domain (Choi
et al., 1996), and FKBP12-TGFI-b receptor cytoplasmic
domain (Huse et al., 1999). Interestingly, recent studies have
demonstrated that the level of FKBP12 in brain is 503 higher
than those in tissues of the immune system, and at the same
time FK506 and rapamycin take neurotrophic effects by
binding to FKBP12 (Dawson et al., 1994; Lyons et al., 1994;
Steiner et al., 1992). Although there is little understanding of
its neuroprotective or neurogenerative mechanism, FKBP12
was still identiﬁed as a drug target and several FK506 analogs
which have neurotrophic activity without immunosuppres-
sive action have been designed and synthesized (Adalsteins-
son and Bruice, 2000; Becker et al., 2000; Gold, 2000; Gold
et al., 1997; Guo et al., 2001; Sabatini et al., 1997; Sauer
et al.,1999; Sich et al., 2000; Steiner et al., 1997a). For a long
time, it has proved difﬁcult to cure stroke sequelae, central and
peripheral nerve injury, and neurodegenerative disorders such
as Alzheimer’s disease and Parkinson’s disease. These
ﬁndings provide a promising future prospect for the treatment
of those diseases.
FK506 possesses one binding domain and one effector
domain, respectively, and binds to FKBP12 via the binding
domain and calcineurin via the effector domain. Its neuro-
trophic effect was only determined by binding domain, un-
related to the effector domain (Kissinger et al., 1995; Snyder
et al., 1998). So several FK506 analogs with neuroregener-
ative properties but lacking immunosuppressive effects,
such as GPI-1046 (Steiner et al., 1997b) and V-10, 367
(Gold et al., 1997) have been synthesized and described.
Research has been done upon the neuroprotective and
neurogenerative effects of GPI-1046 (Zhang et al., 2001),
which will become a widely used drug for neuron injury
therapy. However, there are still some arguments regarding
its suitability for therapeutic use. For example, Winter and
co-workers found that GPI-1046, when compared with
FK506, did not protect against neuronal death and inhibit
c-Jun expression in the substantia nigra pars compacta after
transection of the rat medial forebrain bundle (Winter et al.,
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2000). The mechanism of FK506 as a neurotrophic drug is
still obscure, but designing drugs based on the hydrophobic
pocket conformation of FKBP12 is always an effective
method. Some experiments and our calculations reveal that
the binding constant of GPI-1046 to FKBP12 is 1000-fold
smaller than FK506 (Graziani et al., 1999), which might
explain the results of experiments by Winter and co-workers.
So, new drugs with small molecular weight, easy synthesis,
and higher afﬁnity are still in need of designing and
synthesizing.
High-resolution complex structures of FKBP12 provide
a solid basis for designing new compounds. After structure
analysis and computer-aided drug design (Structure and
Activity Relationship Calculation, i.e., SAR), we designed
and synthesized two new neurotrophic compounds: (3R)-4-
(p-Toluenesulfonyl)-1,4-thiazane-3-carboxylic acid-L-Leu-
cine ethyl ester (which we called compound 308); and
(3R)-4-(p-Toluenesulfonyl)-1,4-thiazane-3-carboxylic acid-
L-phenylalanine benzyl ester (which we called compound
107), which are a little larger than GPI-1046. These two
compounds show better neurotrophic effect according to
neuron growth experiments in vitro than GPI-1046 (data was
provided by Professor Song Li). Fluorescence measurements
showed these two compounds can bind to FKBP12 effec-
tively, controlled by the rapamycin binding effect. Crystal
structures of FKBP12 complexed with these two compounds
were obtained to investigate in more detail the interaction
between FKBP12 and these two ligands. From structure
analysis and comparison, obvious effects of volume and
surface area and considerable changes of atom contacting
numbers were observed, presumably causing different bind-
ing energy for different compounds. As a result, we conclude
that these new designed compounds show a better aspect
in neuron-protective drug development than GPI-1046. Our
work also reveals that volume and surface area changes
resulting from ligand binding to protein are a distinguished
factor for designing efﬁcient compounds to serve as protein
inhibitors.
MATERIALS AND METHODS
Molecular design
Conformations of FK506 and rapamycin complexed to FKBP12, re-
spectively, have been discussed and compared in detail earlier (Denesyuk
et al., 1998), and many compounds have been designed according to the
structure of FK506 or rapamycin (Becker et al., 1999, 1993; Christner et al.,
1999; Hauske et al., 1992). However, there are a few weak arguments upon
structure analysis in detail when designing new drugs. Our strategy was to
ﬁrst make molecular design with further analysis based on the complex
structures of FKBP12-FK506 and FKBP12-rapamycin. After that, we
introduce two potential compounds as new inhibitors of FKBP12. The
afﬁnities of these two potential compounds were then compared to the
afﬁnities of FK506, rapamycin, and GPI-1046 using Quantitative Structure-
Activity Relationships (QSAR) calculations.
Most FKBPs possess peptidal prolyl cis/trans isomerase (PPIase) activity
and might play important roles as chaperones in the restructuring of proteins
(Schiene and Fischer, 2000). The conformation of the FKBP binding pocket
is speciﬁc and facile for Leu-Pro-X peptide segment (where X is a
hydrophobic residue such as Leu, Ile, or Val) to bind and change the cis/trans
conformation of prolyl, helping the protein to fold well. In FKBP12, the
hydrophobic pocket is formed by Tyr82, Ile92, Phe36, Phe99, Tyr26, Phe46,
Phe48, Val55, Ile56, and Trp59, and its volume can only accommodate
a ﬁve-membered or six-membered ring (Fig. 1). Inspecting the complex
structures of FKBP12-FK506 and FKBP12-rapamycin, the correspondent
part ﬁtting this pocket is obviously the six-membered pipecolinyl ring of
FK506 or rapamycin (Denesyuk et al., 1998), so it is necessary to keep this
important structure character in new designed ligands.
Further design was based on the detailed investigation of close contacts
between FKBP12 and known inhibitors (FK506 and rapamycin). We
extracted close atom pairs (Table 1) between protein and ligand according to
the cutoff criterion. That is to say, if the distance between two atoms is
smaller than the sum of three radii, i.e., the two atoms’ radii and the one
water molecule radius (2.8 A˚), this atom pair will be included. From the
listing of close contacts, many contacts are formed among Tyr82, Ile56,
Val55, Glu54, and Asp37, and several atoms around the pipecolinyl ring. To
design a more efﬁcient compound, these close contacts/interactions should
be preserved and more close contacts need to be designed to enhance the
binding afﬁnity.
Based on the principle discussed above, we tried to design two
compounds as shown (Fig. 2). One is (3R)-4-(p-Toluenesulfonyl)-1,4-
thiazane-3-carboxylic acid-L-Leucine ethyl ester and the other one is (3R)-4-
(p-Toluenesulfonyl)-1,4-thiazane-3-carboxylic acid-L-phenylalanine benzyl
ester. For brevity, we called these two compounds 107 and 308, respectively.
Following molecular design, these two compounds were synthesized as
FIGURE 1 Stereo view of the binding pocket of
FKBP12 formed by the hydrophobic residues Ile91,
Phe36, Phe99, Tyr26, Phe46, Phe48, Val55, Ile56,
Tyr82, and Trp59.
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described. (Data was provided by Professor Song Li and preserved in Patent
No. 01142744-2, China.)
Docking
The crystal structures of FKBP12 in complex with FK506 (Wilson et al.,
1995), rapamycin (Wilson et al., 1995), and GPI-1046 (Sich et al., 2000)
were taken from the Brookhaven Protein Data Bank (entries 1FKJ, 1FKL,
and 1F40, respectively). The polar hydrogen model was chosen for
FKBP12. The charges of proteins and ligands were assigned with
Kollman-united and Gasteiger-Hu¨ckel charges, respectively. The hydrogens
and charges were added using molecular modeling software SYBYL, rel. 6.7
(SYBYL 2000, Tripos, St. Louis, MO).
The advanced docking program AutoDock 3.01 (Morris et al., 1998) was
used to evaluate the binding free energy of these ﬁve inhibitors (FK506,
GPI-1046, rapamycin, 107, and 308) with FKBP12 (Table 2). AutoDock
3.01 includes a new genetic algorithm search engine and an empirical free
energy function for estimating binding free energies and inhibition constants
(Ki). Four binding energy terms were included in the score function:
electrostatic, Van der Waal, hydrogen bonding, and desolvation effect. The
binding free energy was empirically calculated based on these energy terms
and a set of coefﬁcient factors (Morris et al., 1998).
The whole docking process could be summarized as follows. Firstly, the
macromolecules were checked for polar hydrogens and assigned for partial
atomic charges, and the atomic solvation parameters were also assigned for
the macromolecules. Meanwhile, the torsion angles of the inhibitors during
molecular docking were deﬁned. Secondly, the three-dimensional grid was
created by AutoGrid algorithm (Morris et al., 1998) to evaluate the binding
energies based on macromolecular coordinates. At this stage, the FKBP12
was embedded in the three-dimensional grid and a probe atom was placed at
each grid point. The afﬁnity and electrostatic potential grid were calculated
for each atom type present in the inhibitors. The energetics of a given
inhibitor conﬁguration was found by tri-linear interpolation of afﬁnity values
and electrostatic interaction of the eight grid points surrounding each of the
atoms in an inhibitor. Finally, AutoDock 3.01 (Morris et al., 1998, 1999)
was used to calculate the binding energy of a given ligand conformation in
the crystal/NMR structure while the probable structure inaccuracies were
ignored in the calculations. All computer simulations were performed on
Silicon Graphics R10000 workstations.
Fluorescence quenching
Recombinant human FKBP12 was expressed in Escherichia coli and
puriﬁed as described (Pei et al., 2000). The solution of FKBP12 can
ﬂuoresce at 310–340 nm when irradiated with ultraviolet light at 295 nm as
described (Park et al., 1992). The ﬂuorescence of FKBP12 solution is caused
by its buried tryptophan residue Trp59, which is located at the bottom of its
binding pocket. Another three tyrosine residues—Tyr82 and Tyr26 located
TABLE 1 Count of contact atom pairs between FKBP12 and inhibitors from ﬁve complexes
16 Pairs 23 Pairs 22 Pairs 27 Pairs 33 Pairs
FKBP12 FK506 FKBP12 Rapamycin FKBP12 GPI1046 FKBP12 107 FKBP12 308
Tyr26 CE2 O4 Tyr66 CE1 O4 Tyr26 CE2 C5 Tyr26 CZ C7 Tyr26 CE1 O5
Phe36 CE1 O4 Phe36 CE1 O4 CZ C4 Phe46 CE1 S1 CE2 S1
Asp37 CB O6 Asp37 CB O6 OH C5 Glu54 C O5 CZ S1
CG O6 CG O6 OH C4 O O5 Phe36 CE2 O4
OD2 O4 OD2 O4 Phe46 CE2 C3 Val55 N O5 Glu54 O C6
OD2 O5 OD2 O5 CZ C3 CA O2 Val55 CA O1
OD2 O6 OD2 O6 Glu54 O O1 CA O5 CB O1
Glu55 O O10 Phe46 CZ O11 Val55 CG1 O1 CB O2 C O1
Val55 CA O2 Glu53 O O13 Tyr82 CE1 C15 C O2 C O10
C O2 Glu54 CA O10 CZ C15 C O5 Ile56 N O1
CB O2 C O10 OH O2 Ile56 N O2 N C9
Ile56 N O2 O O10 OH C15 CG2 C22 N C10
CG2 O2 O C30 OH C7 TRP59 CD2 S1 CA C10
Trp59 CE2 C3 Val55 CA O2 OH O7 CE2 C6 CB C10
Tyr82 OH C42 C O2 His87 CG C11 CE2 S1 CG2 O2
OH O3 C O41 ND1 C11 NE1 C6 CG2 C9
CB O2 CD2 C10 Tyr2 CE2 O1 CG2 C10
CG1 O11 CD2 C11 CE2 C22 CG1 O1
Ile56 N O2 CE1 C10 CZ O1 TRP59 CD2 C4
Tyr82 OH C1 CE1 C11 OH C1 CE2 C4
OH O1 NE2 C10 OH N1 NE1 C4
OH O3 NE2 C11 OH O1 CZ2 C4
OH C49 OH C5 Tyr82 CE2 O2
OH C10 CE2 C9
His87 CD2 C11 CZ O2
Phe99 CE2 O4 CZ C9
CZ O3 OH C3
OH C5
OH N2
OH O2
OH C9
OH C18
Phe99 CZ O4
Each residue/atom label is in accordance with the respective PDB ﬁles.
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around the pocket, and Tyr80 near the pocket—alsomake a little ﬂuorescence
contribution to this excitation and emission wavelength. After the inhibitor
was added and bound to the pocket, the polar environment around Trp59
would change, resulting in ﬂuorescence quenching. 30-mM protein buffered
with 5 mMNaH2PO4 of pH 6.5 and 100 mMNaCl was prepared to measure
the initial ﬂuorescence at 258C. Inhibitors (rapamycin, 308, and 107) were
added respectively to make the titration for ﬂuorescence quenching. The
ﬂuorescence changes at an emission wavelength of 320 nm were calculated
and normalized according to each saturated quenching. These changes were
then plotted against inhibitor concentration (Fig. 3). All the ﬂuorescence
measurements were carried out by using AMINCO-Bowman Series 2
Luminescence Spectrometer (Thermo Electron) and data was processed by
Excel 2000 (Microsoft).
Crystallization and crystal preparation
The puriﬁed protein in 10 mM cacodylic acid sodium (pH 6.5) was in-
cubated with compounds 308 and 107, respectively, for 12 h at 48C, in 1:1.2
molar ratio. Then the complex protein was concentrated to 20 mg/ml.
Crystallization of FKBP12 complexed with 308/107 was carried out using
the hanging-drop vapor-diffusion method at 188C. 2-ml drops of complexed
protein solution were mixed with 2-ml reservoir solution containing 15–27%
PEG 10,000, 0.1 MHEPES Na (pH 7.5). Rod-like crystals appeared after six
days and the microseeding method was used to obtain larger single crystals
(Li et al., 2002, 2003).
Data collection and processing
Crystals were ﬂash-frozen with liquid nitrogen, using the mother liquor as
cryoprotectant. Data were collected using a MarResearch image plate on
a Rigaku 18-kW rotating anode generator, operating at 48 kV and 90 mA
with monochromated radiation (l ¼ 1.5418 A˚).
Data processing was performed using the program DENZO and data sets
were scaled and merged using SCALEPACK (Otwinowski and Minor
FIGURE 2 The schematic procedure of designing new
inhibitors only with neurotrophic effect from the structures
of FK506 and rapamycin. The part marked by blue refers
to the core structure ﬁtting to the binding pocket; the parts
marked by green and red have many interactions with
protein, which were polished for stronger binding; and the
left parts, marked by other colors, have great changes after
designing to increase the hydrophobic interactions be-
tween ligands and protein.
TABLE 2 Calculated binding energy, molecular weight, and
dissociation constant for ﬁve inhibitor compounds
Compound
Calculated
binding energy
(kcal/mol)
Molecular
weight (Da)
Dissociation
constant from
literature (mM)*
GPI-1046 4.94 359.5 1.6
FK506 9.23 820 0.0016
Rapamycin 12.52 1040.5 0.0035y
107 9.39 538.7 N/A
308 8.3 442.6 N/A
*All dissociation constants refer to the data from Graziani et al. (1999).
yThis is the IC50 of rapamycin with the order of its dissociation constant.
FIGURE 3 The ﬂuorescence quenching at 320 nm against different
inhibitor concentrations. All the ﬂuorescence changes were normalized for
comparison among rapamycin, 308, and 107.
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1997). The crystal of FKBP12-308 complex belongs to space group P21, a¼
41.2 A˚, b ¼ 29.6 A˚, c ¼ 41.5 A˚, and b ¼ 1148, containing one molecule per
asymmetric unit and 36% solvent. And the crystal of FKBP12-107 complex
also belongs to space group P21, a ¼ 42.0 A˚, b ¼ 30.4 A˚, c ¼ 42.4 A˚, and
b ¼ 110.78, containing one molecule per asymmetric unit and 42% solvent
(Li et al., 2002, 2003). All backbone conformation angles are in the fully
allowed region of the Ramachandran Plot. An analysis of side-chain
conformation angles for the reﬁned structures shows very good statistics
according to the program PROCHECK (Laskowski et al., 1993).
RESULTS AND DISCUSSION
QSAR analysis
To compare the potency of compounds 107 and 308 with
FK506, rapamycin, and GPI-1046, the binding free energy
for each of these ﬁve inhibitors binding with FKBP12 was
evaluated (Table 2) with SAR calculation, using advanced
docking program AutoDock 3.01 (Morris et al., 1998).
Rapamycin has the lowest binding energy and GPI-1046 is
the weakest one. QSAR analysis clearly revealed that both
compounds 107 and 308 possess a signiﬁcant higher binding
afﬁnity than GPI-1046 when binding to FKBP12. Further-
more, compound 107 has the same binding afﬁnity as
FK506, but has a much smaller molecular weight than
FK506. Taking binding energy and molecular weight into
account, compound 308 would be the best drug candidate
with a high afﬁnity and low weight. Above all, the calcula-
tion showed a good aspect for these two small molecules and
it is necessary to synthesize them and make a more detailed
investigation of their function by experiments.
Binding afﬁnity estimation by ﬂuorescence
quenching experiment
According to the systematic error of concentration measure-
ments, we opted not to calculate the accurate dissociation
constants of these inhibitors using Scatchard analysis. In-
stead, we normalized these ﬂuorescence-quenching changes
to put them on the same scale. On this normalized scale, the
same change will refer to the same concentration ratio
between bound protein and total protein ð½EI=½E0Þ: In other
words, for [E]0 ¼ [EI ] 1 [E], the same ratio between bound
protein and free protein ð½EI=½EÞ will occur. According
to the equilibrium equation for protein-inhibitor binding
ðKd ¼ ½E½I=½EIÞ; the ratio of dissociation constants for
different inhibitors could be estimated by the ratio of in-
hibitor concentrations. Following this principle, we calcu-
lated these ratios. The result indicates that the dissociation
constant of 308 is;40-fold larger than that of rapamycin and
107 is ;200-fold larger than rapamycin. According to
Graziani’s data (Table 2, this article; see also Graziani et al.,
1999), the binding afﬁnity of rapamycin to FKBP12 is more
than 1000-fold larger than GPI-1046. So, consideration of
these data together reveals that the binding afﬁnity of 308 to
FKBP12 is at least 25-fold larger than GPI-1046 and 107 is
at least ﬁvefold larger.
Structure determination and reﬁnement
The two complex structures were solved by molecular re-
placement by using the program CNS (Bru¨nger et al., 1998),
with a starting model from the x-ray structure of FKBP12-
DMSO complex (PDB:1D7H). The DMSO molecule and all
water molecules were discarded and the temperature factors
of all remaining atoms were ﬁxed at 20.0 A˚2. The rotation
and translation function calculation was carried out using the
data within the resolution range 15–3.5 A˚.
The model was rebuilt with O and reﬁned with CNS. After
a rigid body reﬁnement, s-A-weighted 2jFOj  jFCj and
jFOj  jFCj difference maps were used to locate the ligands
and solvent molecules. Using the 40–1.8 A˚ data, 2jFOj  jFCj
and jFOj  jFCj electron density maps were calculated and
examined with O. The reﬁnement was completed by alter-
nating between manual building and minimization using data
in the resolution range 40–1.8 A˚. After reﬁnement, the ﬁnal
R-value and R-free value was 0.19 and 0.22, respectively, for
FKBP12-308 complex structure, and 0.21 and 0.26, re-
spectively, for FKBP12-107 complex structure (Table 3).
Crystal structure of FKBP12
complexed with ligands
Mass spectrometry was used to observe the speciﬁc binding
between each compound and FKBP12 as described (data
was provided by Professor Song Li). To study the detailed
interaction between FKBP12 and its inhibitor, we co-crystal-
TABLE 3 Crystallographic data and reﬁnement statistics
Data and statistics FKBP12-308 FKBP12-107
Resolution (A˚) 50–1.8 50–1.8
Space group P21 P21
Unit cell constants a ¼ 41.2 A˚ a ¼ 42.0 A˚
b ¼ 29.6 A˚ b ¼ 30.4 A˚
c ¼ 41.5 A˚ c ¼ 42.4 A˚
b ¼ 1148 b ¼ 110.78
Total number of reﬂections 83830 32811
Number of unique reﬂections 9385 (769*) 9478 (773*)
I/sI 18.6 (6.9*) 17.2 (4.9*)
Redundancy 8.9 (8.9*) 3.5 (3.3*)
Rmerge
y (%) 7.3 (24.8*) 5.2 (29.1*)
Completeness (%) 99.9 (99.7*) 99.6 (98.1*)
Rwork
z/Rfree
§ 0.19/0.22 0.21/0.26
RMS bond length deviation
(A˚)
0.019 0.019
RMS bond angle deviation (8) 2.10 1.98
Solvent molecules 119 133
Average B-factor (A˚2) 15 17
*Numbers in parentheses correspond to the highest resolution shell (2.07–
2.0 A˚).
yRmerge ¼ ShkljIiImj/Shkl Im, where Ii and Im are the observed intensity and
the mean intensity of related reﬂections, respectively.
zRworking ¼ S(kFp(obs)jjFp(calc)k)/SjFp(obs)j; Rfree ¼ R-factor for a selected
subset (10%) of the reﬂections that was not included in prior reﬁnement
calculations.
§10% of the total reﬂections were used for Rfree calculation.
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lized FKBP12 with each compound and obtained good
crystals (Li et al., 2002, 2003). The complexes’ structures
were solved to a high resolution (1.8 A˚) and small ligands
showed good occupancy according to the calculated omit
map (Fig. 4, a and b).
Detailed interactions of the complex structures of FKBP12
with 107, 308, FK506, and rapamycin have been compared.
The interactions among them are approximately the same in
ﬁve/six-membered ring part, which takes accord with the
initial design. Three hydrogen bonds are involved in 308
binding to FKBP12 (Table 4): from Ile56 amide (N) to C5
carbonyl (O1), from Tyr82 hydroxyl (O) to C5 acetyl amide
(N2), and from Tyr82 hydroxyl (O) to C8 ester (O2). There
are also three observed hydrogen bonds between 107 and
FKBP12 (Table 4): from Ile56 amide (N) to C1 carbonyl
(O2), from Tyr82 hydroxyl (O) to C3 ester (O1), and from
Tyr82 hydroxyl (O) to C1 acetyl amide (N1). The above
atom labels take accord with the structure of each inhibitor
compound in PDB. Six or seven hydrophobic contacts be-
tween the protein and 107/308 were observed (Table 4). The
contacts between FKBP12 and ligands were counted by the
same way described above and listed in Table 1. Compared
with FK506 and rapamycin, there are a lot of additional close
contacts for 107 and 308, coming from Val55, Ile56, Trp59,
and Tyr82, which suggest that the binding is stronger for
these two new compounds. Obviously, the additional inter-
actions are mainly due to the additional parts of the designed
compounds, which are colored with red, yellow, and cyan,
respectively (Fig. 2).
Compared with the structure of FKBP12-GPI–1046
complex, both 107 and 308 show a similar binding way.
They all form a hydrogen bond with Tyr82 hydroxyl. How-
ever, for GPI-1046, the lack of conservative hydrogen bonds
with Ile56 and fewer hydrophobic contacts (Table 4) make
this small molecule a weaker inhibitor of FKBP12, which is
highly consistent with our AutoDock score and ﬂuorescence
quenching analysis.
The lower B-factor of the protein when complexed with
inhibitors suggests the binding could stabilize the confor-
mation of FKBP12, resulting in good afﬁnity. The average
B-factor of the free protein was 31 A˚2 and reduced to 17 A˚2
after binding with compound 107, 15 A˚2 after binding to
compound 308, 13 A˚2 for FK506, and 21 A˚2 for rapamycin.
The ﬂexibility of an 80-s loop composed of residues from 82
to 95 in free FKBP12 allows the ligand to enter the bind-
ing cavity easily. This would be accompanied with small
conformation changes, which might cause obvious surface
area, interacting area, and molecular volume effects. To
study this area and volume effect, the accessible surface
areas of FKBP12 (in free state or complex state), the ligands
(FK506, rapamycin, GPI-1046, 107, and 308), and the
complexes were calculated, respectively, by the program
GRASP (Nicholls et al., 1991). The molecular volume for
free protein, ligand, and complex was also calculated in the
same way. Comparing these parameters, we can see the
molecular volume of FKBP12 and the whole system volume
increased (Fig. 5, a and b) on binding to a small ligand,
which is obviously disadvantageous for ligand binding since
this effect will increase the system energy. However, the
accessible area of the system decreased (Fig. 5 c) after ligand
binding, which is favorable to reduce the system energy and
form a good interaction. To combine these two opposite
FIGURE 4 The 2jFoj  jFcj stimulated electron density
maps with ligand omitted. (a) Omit map for 107; (b) omit
map for 308.
TABLE 4 Hydrogen bonds and hydrophobic interactions between FKBP12 and inhibitors from ﬁve complexes
Compound Tyr26 Phe36 Phe46 Glu54 Val55 Ile56 Trp59 Tyr82 His87 Ile90 Ile91
GPI_1046 1 1 1 1 hb 1 1
FK506 1 1 1 hb 1 hb 1 1
Rapamycin 1 1 1 1 1 hb 1 hb 1 1
107 1 1 1 hb 1 hb 1 1
308 1 1 1 1 hb 1 hb 1 1
hb ¼ hydrogen bond; 1 ¼ hydrophobic interaction.
New Potential FKBP12 Inhibitors 3199
Biophysical Journal 85(5) 3194–3201
effects, we introduce a parameter r deﬁned as follows: r ¼
Darea/Dvolume, where delta-area and delta-volume represent
differences in accessible area and molecular volume,
respectively. According to this r-value, which could approx-
imate the binding afﬁnity, it seems that 308 owns highest
afﬁnity to FKBP12 among GPI-1046, 107, and 308 (Fig.
5 d ). From this surface and volume analysis, GPI-1046 was
still the worst one when binding to FKBP12, which is also
consistent with AutoDock calculation, ﬂuorescence quench-
ing experiments, and contacts analysis.
CONCLUSION
Both compounds 107 and 308 were designed based on the
complex structures of FKBP12-FK506 and FKBP12-rapa-
mycin by using the following guiding principles: the core
structure formed by a six-member ring is essential when
binding to protein; more polar atoms, e.g., N and O, were
added to try to increase electrical interaction; and more
acyclic or alicyclic groups were designed to try to increase
hydrophobic interactions.
In principle, volume and surface effect should be taken
into consideration when investigating the interactions
between protein and ligands, which might be responsible
for the binding energy. Assuming the structure determination
errors are not large enough to dominate this probably im-
portant effect, the analysis above indicates that compounds
308 and 107 had larger volume/surface effects than GPI-
1046 in principle. Structure comparisons show that the
binding afﬁnity of 308 is [107, which is in accord with
ﬂuorescence analysis, but different from AutoDock score.
This discrepancy might be due to the limitations of the
energy calculation items, which only included electrostatic,
Van der Waal, hydrogen bonding energies and desolvation
effect, but did not include volume/surface effects resulting
from conformational changes. However, when the results of
AutoDock calculation, ﬂuorescence quenching, and crystal-
lographic analysis were combined, we conclude that these
two compounds are new potent inhibitors of FKBP12 with
higher afﬁnity than GPI-1046, and might become alternative
drug candidates in place of GPI-1046.
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